TiumBio Co (321550.KQ) Stock Price

TiumBio Co Price

CLOSED
4,480.00
​
Market closed

Revenue has compounded at 64.8% per year over the past 8 years to 12.29 B KRW. TiumBio Co's net margin stands at -141.3%, up from -55,701.7% several years earlier.

TiumBio Co stock price

Access this data via the Eulerpool API

TiumBio Co business model & stock analysis

TiumBio Co., Ltd. engages in the development and manufacture of therapeutic drugs. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2019-11-22. The firm researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.

Frequently asked questions about TiumBio Co

Converted at the current exchange rate, the TiumBio Co share trades at 2.91 EUR (4,480.00 KRW).

The revenue cannot currently be calculated for TiumBio Co.

The profit cannot currently be calculated for TiumBio Co.

The P/E ratio cannot be calculated for TiumBio Co at the moment.

The P/S cannot be calculated for TiumBio Co currently.

The Eulerpool Quality Score for TiumBio Co is 3/10.

The ISIN of TiumBio Co is KR7321550006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of TiumBio Co is 321550.KQ. The ticker symbol is used to trade TiumBio Co shares on the stock exchange.

Fair ValueTerminal
3,718.40 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website tiumbio.com
Country
South Korea
Currency
KRW
Initial public offering
Nov 22, 2019
ISIN
KR7321550006
Cusip
Y8T41Y101
Market capitalization
115.74 B KRWLarge Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
2.84
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-32.03 %
Gross Margin
41.05 %
EBIT Margin
-103.69 %
Net Margin
-141.27 %
EPS (Earnings Per Share)
-590.44 KRW
Net Debt / EBIT
-0.21
Debt/Equity
0.33
Last updated Oct 2, 2026, 3:16 AM

TiumBio Co Peer Group

TiumBio Co FIGI

321550:KS · BBG00L19Z389321550:KQ · BBG00QKHSZ95